A preclinical study by neuroscientists indicates that an antigen-presenting dendritic vaccine with a specific antibody response to oligomeric A-beta may be safer and offer clinical benefit in treating Alzheimer's disease. The vaccine uses immune cells known as dendritic cells loaded with a modified A beta peptide as the antigen.
from Health & Medicine News -- ScienceDaily https://www.sciencedaily.com/releases/2020/10/201020135637.htm
No comments:
Post a Comment